We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott (ABT) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
In the latest trading session, Abbott (ABT - Free Report) closed at $77.54, marking a +1.85% move from the previous day. This change lagged the S&P 500's 2.14% gain on the day. Elsewhere, the Dow gained 2.06%, while the tech-heavy Nasdaq added 2.65%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 4.25% in the past month. In that same time, the Medical sector lost 3.29%, while the S&P 500 lost 6.63%.
Investors will be hoping for strength from ABT as it approaches its next earnings release. The company is expected to report EPS of $0.80, up 9.59% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.99 billion, up 2.82% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.22 per share and revenue of $31.92 billion. These results would represent year-over-year changes of +11.81% and +4.4%, respectively.
Investors should also note any recent changes to analyst estimates for ABT. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ABT is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that ABT has a Forward P/E ratio of 23.54 right now. This represents a discount compared to its industry's average Forward P/E of 25.4.
Also, we should mention that ABT has a PEG ratio of 2.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.22 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Abbott (ABT) Gains But Lags Market: What You Should Know
In the latest trading session, Abbott (ABT - Free Report) closed at $77.54, marking a +1.85% move from the previous day. This change lagged the S&P 500's 2.14% gain on the day. Elsewhere, the Dow gained 2.06%, while the tech-heavy Nasdaq added 2.65%.
Coming into today, shares of the maker of infant formula, medical devices and drugs had lost 4.25% in the past month. In that same time, the Medical sector lost 3.29%, while the S&P 500 lost 6.63%.
Investors will be hoping for strength from ABT as it approaches its next earnings release. The company is expected to report EPS of $0.80, up 9.59% from the prior-year quarter. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.99 billion, up 2.82% from the year-ago period.
ABT's full-year Zacks Consensus Estimates are calling for earnings of $3.22 per share and revenue of $31.92 billion. These results would represent year-over-year changes of +11.81% and +4.4%, respectively.
Investors should also note any recent changes to analyst estimates for ABT. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. ABT is currently a Zacks Rank #3 (Hold).
Valuation is also important, so investors should note that ABT has a Forward P/E ratio of 23.54 right now. This represents a discount compared to its industry's average Forward P/E of 25.4.
Also, we should mention that ABT has a PEG ratio of 2.13. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Medical - Products was holding an average PEG ratio of 2.22 at yesterday's closing price.
The Medical - Products industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 84, which puts it in the top 33% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.